A Phase I, Multi-center, Open-label, Study to Investigate the Safety, Tolerability and Pharmacokinetic of SLC-0111 in Subjects With Advanced Solid Tumours
Phase of Trial: Phase I
Latest Information Update: 26 May 2016
Price : $35 *
At a glance
- Drugs SLC 0111 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors SignalChem Lifesciences; Welichem Biotech
- 13 May 2016 Status changed from recruiting to completed.
- 08 Dec 2015 Planned number of patients changed from 34 to 24 as reported by ClinicalTrials.gov.
- 16 Nov 2015 Planned end date changed from 1 Mar 2016 to 1 Apr 2016, as reported by ClinicalTrials.gov.